Switching from Dupilumab to Upadacitinib in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis After Inadequate Response to Dupilumab: Efficacy and Safety Results from Period 2 of Phase 3b/4 Study (LEVEL UP). - Bunick CG; Magnolo N; Moore A; Abe M; Gao X; Lynde C; Ibrahim N; Levy G; Calimlim BM; Wu X; Armendariz Y; Grada A; et al. (American journal of clinical dermatology, 2026)